FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2205909617> ?p ?o ?g. }

• W2205909617 endingPage "258" @default.
• W2205909617 startingPage "253" @default.
• W2205909617 abstract "A multicenter phase II trial was conducted to assess the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with weekly cisplatin (CDDP) and paclitaxel (PTX) in patients with locally advanced uterine cervical cancer.Patients with FIGO stage III-IVA uterine cervical cancer without para-aortic lymphadenopathy were enrolled. Patients received definitive radiotherapy (RT) consisting of external beam whole-pelvic RT and high-dose-rate intracavitary brachytherapy. The cumulative linear quadratic equivalent dose was 62-65Gy prescribed at point A. weekly CDDP at 30mg/m(2) and PTX at 50mg/m(2) were administered concurrently with RT for ≥5 courses.Sixty-eight of the 70 registered patients were eligible. The complete response rate was 76.5% (95% confidence interval [CI], 66.4-86.6%). With a median follow-up of 27months (range, 7.9-33.5), the 2-year cumulative progression-free survival and the 2-year cumulative overall survival rates were 83.8% (95% CI, 75.1-92.6%) and 92.7% (95% CI, 86.4-98.9%), respectively. The pelvic cumulative disease progression-free and the 2-year cumulative distant metastasis rates were 89.6% (95% CI, 82.3-96.9%) and 13.2% (95% CI, 5.2-21.3%), respectively. The 2-year cumulative late complication rates were 25% for all grades, 13.2% for grade 1, 5.9% for grade 2, 2.9% for grade 3, and 2.9% for grade 4.For locally advanced cervical cancer, CCRT with weekly CDDP 30mg/m(2) and PTX at 50mg/m(2) demonstrated favorable antitumor activity, and was feasible and safe with respect to the protocol-specified serious adverse reactions and events. Evaluation of this regimen in phase III trials is warranted." @default.
• W2205909617 created "2016-06-24" @default.
• W2205909617 creator A5004971708 @default.
• W2205909617 creator A5010889533 @default.
• W2205909617 creator A5011364641 @default.
• W2205909617 creator A5012303015 @default.
• W2205909617 creator A5015327594 @default.
• W2205909617 creator A5022237129 @default.
• W2205909617 creator A5036692194 @default.
• W2205909617 creator A5038525164 @default.
• W2205909617 creator A5038650004 @default.
• W2205909617 creator A5048907152 @default.
• W2205909617 creator A5050726729 @default.
• W2205909617 creator A5062470926 @default.
• W2205909617 creator A5065827694 @default.
• W2205909617 creator A5067283980 @default.
• W2205909617 creator A5068679494 @default.
• W2205909617 creator A5076136934 @default.
• W2205909617 creator A5087640271 @default.
• W2205909617 date "2016-02-01" @default.
• W2205909617 modified "2023-09-26" @default.
• W2205909617 title "Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial" @default.
• W2205909617 cites W1935824237 @default.
• W2205909617 cites W1964618314 @default.
• W2205909617 cites W1971646270 @default.
• W2205909617 cites W1974324280 @default.
• W2205909617 cites W1980908298 @default.
• W2205909617 cites W1993717128 @default.
• W2205909617 cites W2014343721 @default.
• W2205909617 cites W2029401467 @default.
• W2205909617 cites W2042262831 @default.
• W2205909617 cites W2048865077 @default.
• W2205909617 cites W2049306821 @default.
• W2205909617 cites W2054292383 @default.
• W2205909617 cites W2061322968 @default.
• W2205909617 cites W2089284180 @default.
• W2205909617 cites W2091790184 @default.
• W2205909617 cites W2095823414 @default.
• W2205909617 cites W2104360894 @default.
• W2205909617 cites W2128559738 @default.
• W2205909617 cites W2131538171 @default.
• W2205909617 cites W2142810471 @default.
• W2205909617 cites W2157372207 @default.
• W2205909617 cites W2157719711 @default.
• W2205909617 cites W2165532518 @default.
• W2205909617 cites W2165653322 @default.
• W2205909617 cites W2314753133 @default.
• W2205909617 cites W2324392028 @default.
• W2205909617 cites W2328935341 @default.
• W2205909617 doi "https://doi.org/10.1016/j.ygyno.2015.12.008" @default.
• W2205909617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26701414" @default.
• W2205909617 hasPublicationYear "2016" @default.
• W2205909617 type Work @default.
• W2205909617 sameAs 2205909617 @default.
• W2205909617 citedByCount "11" @default.
• W2205909617 countsByYear W22059096172017 @default.
• W2205909617 countsByYear W22059096172018 @default.
• W2205909617 countsByYear W22059096172019 @default.
• W2205909617 countsByYear W22059096172020 @default.
• W2205909617 countsByYear W22059096172021 @default.
• W2205909617 countsByYear W22059096172023 @default.
• W2205909617 crossrefType "journal-article" @default.
• W2205909617 hasAuthorship W2205909617A5004971708 @default.
• W2205909617 hasAuthorship W2205909617A5010889533 @default.
• W2205909617 hasAuthorship W2205909617A5011364641 @default.
• W2205909617 hasAuthorship W2205909617A5012303015 @default.
• W2205909617 hasAuthorship W2205909617A5015327594 @default.
• W2205909617 hasAuthorship W2205909617A5022237129 @default.
• W2205909617 hasAuthorship W2205909617A5036692194 @default.
• W2205909617 hasAuthorship W2205909617A5038525164 @default.
• W2205909617 hasAuthorship W2205909617A5038650004 @default.
• W2205909617 hasAuthorship W2205909617A5048907152 @default.
• W2205909617 hasAuthorship W2205909617A5050726729 @default.
• W2205909617 hasAuthorship W2205909617A5062470926 @default.
• W2205909617 hasAuthorship W2205909617A5065827694 @default.
• W2205909617 hasAuthorship W2205909617A5067283980 @default.
• W2205909617 hasAuthorship W2205909617A5068679494 @default.
• W2205909617 hasAuthorship W2205909617A5076136934 @default.
• W2205909617 hasAuthorship W2205909617A5087640271 @default.
• W2205909617 hasConcept C121608353 @default.
• W2205909617 hasConcept C126322002 @default.
• W2205909617 hasConcept C126894567 @default.
• W2205909617 hasConcept C141071460 @default.
• W2205909617 hasConcept C143998085 @default.
• W2205909617 hasConcept C151032500 @default.
• W2205909617 hasConcept C2776694085 @default.
• W2205909617 hasConcept C2777416452 @default.
• W2205909617 hasConcept C2778220009 @default.
• W2205909617 hasConcept C2778239845 @default.
• W2205909617 hasConcept C2778424827 @default.
• W2205909617 hasConcept C31760486 @default.
• W2205909617 hasConcept C44249647 @default.
• W2205909617 hasConcept C509974204 @default.
• W2205909617 hasConcept C71924100 @default.
• W2205909617 hasConcept C90924648 @default.
• W2205909617 hasConceptScore W2205909617C121608353 @default.
• W2205909617 hasConceptScore W2205909617C126322002 @default.
• W2205909617 hasConceptScore W2205909617C126894567 @default.

• next